Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Heartbeam Inc. Warrant (BEATW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: BEATW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.64% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.29 - 0.95 | Updated Date 02/24/2025 |
52 Weeks Range 0.29 - 0.95 | Updated Date 02/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.31% | Return on Equity (TTM) -164.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5185854 |
Shares Outstanding - | Shares Floating 5185854 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Heartbeam Inc. Warrant
Company Overview
History and Background
Heartbeam Inc. is a relatively young company focused on developing advanced cardiac monitoring solutions. The warrant allows the holder to purchase common stock at a specified price. The warrants were issued as part of fundraising efforts.
Core Business Areas
- Cardiac Monitoring Solutions: Development and commercialization of wearable ECG devices for detection of cardiac events.
Leadership and Structure
Information about Heartbeam's leadership team and organizational structure can typically be found on their investor relations website or in SEC filings. These details change frequently, so a direct listing here would be inaccurate without constantly updating.
Top Products and Market Share
Key Offerings
- Heartbeam AIMI Platform: A 3D vector ECG platform intended for detection of acute myocardial ischemia (AMI), also known as a heart attack. Market share data is currently unavailable for this platform as it is pre-commercial. Competitors include traditional ECG manufacturers like GE Healthcare and Philips, as well as emerging remote cardiac monitoring companies. It is difficult to get market share for product in pre-commercial stage.
Market Dynamics
Industry Overview
The cardiac monitoring market is experiencing growth driven by an aging population, increasing prevalence of cardiovascular diseases, and advancements in wearable technology.
Positioning
Heartbeam aims to disrupt the cardiac monitoring market with its novel 3D vector ECG technology, offering improved accuracy and convenience compared to traditional methods.
Total Addressable Market (TAM)
The total addressable market for cardiac monitoring is estimated to be billions of dollars annually. Heartbeam is positioned to capture a share of this market with its innovative technology, targeting early heart attack detection.
Upturn SWOT Analysis
Strengths
- Novel 3D vector ECG technology
- Potential for improved accuracy in detecting cardiac events
- Wearable and convenient design
- Strong intellectual property portfolio
Weaknesses
- Pre-commercial stage, lack of revenue
- Reliance on regulatory approvals
- Limited brand recognition
- Need for further clinical validation
Opportunities
- Growing market for cardiac monitoring solutions
- Potential for partnerships with healthcare providers
- Expansion into remote patient monitoring
- Increasing adoption of wearable technology
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- GE (GE)
- Philips (PHG)
- iRhythm Technologies (IRTC)
Competitive Landscape
Heartbeam faces intense competition from established medical device companies with greater resources and brand recognition. The company's success depends on demonstrating the clinical and economic advantages of its technology.
Growth Trajectory and Initiatives
Historical Growth: As a pre-commercial company, Heartbeam's growth is characterized by development milestones and clinical trial results, not revenue growth.
Future Projections: Future growth depends on successful regulatory approvals, commercialization of products, and market adoption. Analyst estimates are speculative at this stage.
Recent Initiatives: Recent initiatives include clinical trials, regulatory submissions, and strategic partnerships.
Summary
Heartbeam Inc. Warrant represents a high-risk, high-reward investment. The company's innovative technology holds significant potential, but faces regulatory and commercialization challenges. Success hinges on regulatory approvals, market adoption, and the ability to compete with established players. Investors should be aware of the speculative nature of this investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings, Company website, Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heartbeam Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-11 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 15 | Website |
Full time employees 15 | Website | ||
HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company develops three-dimensional (3D)-vector electrocardiogram (ECG) platform for heart attack detection. It is developing HeartBeam AIMI software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack; and HeartBeam AIMIGo, a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.